Market overview
The global vaccines market is worth USD 80.6 bn in 2026 and is forecast to reach USD 158 bn by 2036, growing at a 7.0% CAGR. United States is the largest country market and Childhood combination and others is the largest by disease segment.
| Scope | Vaccines against infectious disease for humans, including childhood, adult, travel, influenza, pneumococcal, HPV, shingles, meningococcal, COVID-19 and RSV vaccines. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 76.0 bn |
| Value 2026 | USD 80.6 bn |
| Value 2036 | USD 158 bn |
| CAGR 2026-2036 | 7.0% |
| Volume 2026 | 6,788 million doses |
| Volume 2036 | 11,506 million doses |
| Average price 2026 | USD 11.9 per dose |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Vaccines market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 80.6 bn |
| 2027 | USD 86.2 bn |
| 2028 | USD 92.2 bn |
| 2029 | USD 98.7 bn |
| 2030 | USD 106 bn |
| 2031 | USD 113 bn |
| 2032 | USD 121 bn |
| 2033 | USD 129 bn |
| 2034 | USD 138 bn |
| 2035 | USD 148 bn |
| 2036 | USD 158 bn |
Vaccines market segmentation
By disease
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Pneumococcal | 17.0% | 15.8% | USD 13.7 bn | 6.2% |
| Influenza | 11.0% | 9.3% | USD 8.9 bn | 5.2% |
| HPV and shingles | 17.0% | 17.4% | USD 13.7 bn | 7.2% |
| COVID-19 | 8.0% | 5.3% | USD 6.4 bn | 2.7% |
| Meningococcal | 7.0% | 6.8% | USD 5.6 bn | 6.7% |
| RSV | 7.0% | 14.7% | USD 5.6 bn | 15.2% |
| Childhood combination and others | 33.0% | 30.7% | USD 26.6 bn | 6.2% |
By technology
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Conjugate and subunit | 52.0% | 51.7% | USD 41.9 bn | 6.9% |
| Live attenuated | 15.0% | 11.8% | USD 12.1 bn | 4.4% |
| Inactivated | 12.0% | 9.0% | USD 9.7 bn | 3.9% |
| mRNA and vector | 21.0% | 27.5% | USD 16.9 bn | 9.9% |
By age
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Paediatric | 36.0% | 30.0% | USD 29.0 bn | 5.1% |
| Adult | 42.0% | 46.0% | USD 33.8 bn | 8.0% |
| Elderly | 22.0% | 24.0% | USD 17.7 bn | 7.9% |
By administration
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Intramuscular | 62.0% | 60.0% | USD 49.9 bn | 6.7% |
| Subcutaneous | 14.0% | 14.0% | USD 11.3 bn | 7.0% |
| Oral and intranasal | 10.0% | 12.0% | USD 8.1 bn | 9.0% |
| Intradermal and other | 14.0% | 14.0% | USD 11.3 bn | 7.0% |
By buyer
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Public programs | 46.0% | 44.0% | USD 37.1 bn | 6.5% |
| Private market | 34.0% | 34.0% | USD 27.4 bn | 7.0% |
| Travel and occupational | 20.0% | 22.0% | USD 16.1 bn | 8.0% |
Top 25 countries for vaccines by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 74.5% of 2026 revenue and the 25 countries below together hold 91.8%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 29.0 bn | 36.0% | USD 57.2 bn | 7.0% |
| 2 | China | USD 8.1 bn | 10.0% | USD 16.6 bn | 7.5% |
| 3 | Germany | USD 4.0 bn | 5.0% | USD 7.6 bn | 6.6% |
| 4 | Japan | USD 4.0 bn | 5.0% | USD 7.0 bn | 5.6% |
| 5 | France | USD 3.2 bn | 4.0% | USD 5.9 bn | 6.2% |
| 6 | United Kingdom | USD 2.8 bn | 3.5% | USD 5.4 bn | 6.7% |
| 7 | Italy | USD 2.4 bn | 3.0% | USD 4.3 bn | 5.9% |
| 8 | Brazil | USD 2.4 bn | 3.0% | USD 5.1 bn | 7.7% |
| 9 | Canada | USD 2.0 bn | 2.5% | USD 3.8 bn | 6.6% |
| 10 | India | USD 2.0 bn | 2.5% | USD 5.2 bn | 10.0% |
| 11 | Spain | USD 1.9 bn | 2.4% | USD 3.8 bn | 7.0% |
| 12 | Mexico | USD 1.9 bn | 2.4% | USD 3.8 bn | 7.0% |
| 13 | Indonesia | USD 1.5 bn | 1.9% | USD 3.6 bn | 9.1% |
| 14 | Turkey | USD 1.2 bn | 1.5% | USD 2.9 bn | 9.1% |
| 15 | Russia | USD 1.0 bn | 1.3% | USD 1.7 bn | 5.3% |
| 16 | Australia | USD 902 mn | 1.1% | USD 1.5 bn | 5.4% |
| 17 | Netherlands | USD 806 mn | 1.0% | USD 1.4 bn | 5.4% |
| 18 | Belgium | USD 733 mn | 0.9% | USD 1.2 bn | 5.4% |
| 19 | Switzerland | USD 669 mn | 0.8% | USD 1.1 bn | 5.3% |
| 20 | South Korea | USD 620 mn | 0.8% | USD 1.0 bn | 5.4% |
| 21 | Argentina | USD 572 mn | 0.7% | USD 1.4 bn | 9.2% |
| 22 | Poland | USD 540 mn | 0.7% | USD 1.3 bn | 9.1% |
| 23 | Pakistan | USD 508 mn | 0.6% | USD 1.2 bn | 9.2% |
| 24 | Thailand | USD 475 mn | 0.6% | USD 1.1 bn | 9.2% |
| 25 | Saudi Arabia | USD 451 mn | 0.6% | USD 1.1 bn | 9.3% |
| Rest of world | USD 6.6 bn | 8.2% | USD 12.0 bn | 6.2% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- GSK
- Pfizer
- Merck
- Sanofi
- Moderna
- CSL Seqirus
- Sinopharm
Group 2: Regional and specialist players
- Serum Institute of India
- Bharat Biotech
- Sinovac
- Takeda
- BioNTech
- Zhifei Biological Products
- CanSino Biologics
- SK bioscience
- Butantan Institute
- Emergent BioSolutions
Group 3: Emerging and niche players
- Novavax
- Valneva
- Bavarian Nordic
- Biological E
- Dynavax
- Vaxcyte
- Walvax Biotechnology
- Bio Farma
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the vaccines market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 7.0% is calculated from the resulting values.
The market is divided by disease, by technology, by age, by administration, by buyer. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the vaccines market?
The global vaccines market is estimated at USD 76.0 bn in 2025 and USD 80.6 bn in 2026.
How fast will the vaccines market grow?
It is forecast to reach USD 158 bn by 2036, a compound annual growth rate of 7.0% from 2026, an increase of USD 77.9 bn.
Which country is the largest market for vaccines?
United States is the largest market by revenue at USD 29.0 bn in 2026, 36.0% of the global total. The three largest countries together hold 51.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 10.0% a year from 2026 to 2036.
Which vaccines segment is largest?
In the by disease split, Childhood combination and others is the largest segment with 33.0% of 2026 revenue.
Who are the leading vaccines companies?
Global leaders include GSK, Pfizer, Merck, Sanofi.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- ImmunotherapyUSD 77.7 bn · 8.5% CAGR
- Cardiovascular DevicesUSD 83.8 bn · 7.0% CAGR
- Contract Research OrganizationUSD 91.8 bn · 8.0% CAGR
- Generic InjectableUSD 93.3 bn · 6.3% CAGR
- Revenue Cycle ManagementUSD 68.8 bn · 11.0% CAGR
- Drug Delivery SystemsUSD 67.0 bn · 8.0% CAGR
- Diabetes DrugsUSD 97.5 bn · 5.0% CAGR
- Orthopedic DevicesUSD 65.1 bn · 5.0% CAGR